1. HIV-1 genetic diversity and primary drug resistance mutations before large-scale access to antiretroviral therapy, Republic of Congo.
- Author
-
Niama FR, Vidal N, Diop-Ndiaye H, Nguimbi E, Ahombo G, Diakabana P, Bayonne Kombo ÉS, Mayengue PI, Kobawila SC, Parra HJ, and Toure-Kane C
- Subjects
- Adolescent, Adult, Anti-HIV Agents pharmacology, Child, Child, Preschool, Congo, Female, Gene Expression, Genes, pol, HIV-1 classification, HIV-1 drug effects, HIV-1 isolation & purification, Humans, Male, Molecular Typing, Mutation, Reassortant Viruses classification, Reassortant Viruses drug effects, Reassortant Viruses isolation & purification, Recombination, Genetic, Drug Resistance, Viral genetics, Genetic Variation, Genotype, HIV Infections virology, HIV-1 genetics, Reassortant Viruses genetics
- Abstract
Background: In this work, we investigated the genetic diversity of HIV-1 and the presence of mutations conferring antiretroviral drug resistance in 50 drug-naïve infected persons in the Republic of Congo (RoC). Samples were obtained before large-scale access to HAART in 2002 and 2004., Methods: To assess the HIV-1 genetic recombination, the sequencing of the pol gene encoding a protease and partial reverse transcriptase was performed and analyzed with updated references, including newly characterized CRFs. The assessment of drug resistance was conducted according to the WHO protocol., Results: Among the 50 samples analyzed for the pol gene, 50% were classified as intersubtype recombinants, charring complex structures inside the pol fragment. Five samples could not be classified (noted U). The most prevalent subtypes were G with 10 isolates and D with 11 isolates. One isolate of A, J, H, CRF05, CRF18 and CRF37 were also found. Two samples (4%) harboring the mutations M230L and Y181C associated with the TAMs M41L and T215Y, respectively, were found., Conclusion: This first study in the RoC, based on WHO classification, shows that the threshold of transmitted drug resistance before large-scale access to antiretroviral therapy is 4%.
- Published
- 2017
- Full Text
- View/download PDF